Alexander Pasteur
InvestorPartner at F-Prime Capital Partners
United Kingdom
Writes $100K β $10M checks Β· typically $5M
About
Alex Pasteur is a Partner at F-Prime, which he joined in 2012, and concentrates on therapeutics and life sciences investments. He has worked in healthcare investing since 2001, including a prior role at MVM Life Science Partners LLP in the USA and Europe. He holds an M.A. in Natural Sciences and a PhD in Chemistry, both from Cambridge University.
Invests in
BiotechDigital Health
Experience
- F-Prime Capital PartnersPartnercurrent2012 β presentLondon, United Kingdom
- Tenpoint Therapeutics, Ltd.Non Executive Directorcurrent2020 β presentLondon, England, United Kingdom
- NodTheraNon Executive Directorcurrent2018 β presentBoston, Massachusetts, United States
- GenomicsNon Executive Directorcurrent2018 β presentOxford, England, United Kingdom
- PeptoneNon Executive Directorcurrent2022 β presentLondon Area, United Kingdom
- PulmocideNon Executive Directorcurrent2013 β presentLondon, United Kingdom
- Shift BioscienceNon Executive Directorcurrent2022 β present
- CastorBoard Observercurrent2021 β presentAmsterdam, North Holland, Netherlands
- ARTBIONon Executive Directorcurrent2021 β presentBoston, MA
- OwkinNon Executive Directorcurrent2019 β presentParis
- OvivaNon Executive Director2016 β 2026Zurich, Switzerland
- Arvelle Therapeutics (Acquired by Angelini Pharma in 2021)Non Executive Director (took over from late Tom Beck)2020 β 2021Zug, Switzerland
- Orchard Therapeutics (NASDAQ: ORTX) acquired by Kyowa Kirin in 2023Founding CEO, then Non Executive Director2015 β 2018London, United Kingdom
- Acacia Pharma (EURONEXT BRUSSELS: ACPH) acquired by Eagle Pharmaceuticals in 2022Non Executive Director2013 β 2018Cambridge, United Kingdom
- AdaptimmuneBoard Observer, Adaptimmune Therapeutics PLC (NASDAQ: ADAP)2015 β 2016Oxford, United Kingdom
- MVMPartner2005 β 2012London and Boston
- Gateway FundInvestment Manager2001 β 2005Cambridge, United Kingdom
- OC&CConsultant1996 β 1999London, United Kingdom
Education
- University of CambridgePhD, Chemistry1992 β 1996
- University of CambridgeMaster of Arts (MA), Natural Sciences1989 β 1992
Skills & more
+12 more
Emerging MarketsEntrepreneurshipFinancial ModelingHealthcareInvestment BankingInvestmentsInvestor RelationsLife SciencesRStrategic PlanningStrategyLifesciencesFrom Alexander's professional profile.
Same school
Also attended University of Cambridge621
+ 615 more
Shared employers
Also worked at NodThera4
Also worked at Peptone2
Also worked at Shift Bioscience1
Investments
Board seats
Acacia PharmaAdaptimmune TherapeuticsArvelle TherapeuticsCastorGenomics LtdNodthera, Inc.Oviva AGOwkin, Inc.Peptone LtdPulmocide LtdShift Bioscience Ltd
Investor
ARTBIO, Inc.Orchard Therapeutics PLCTenpoint Therapeutics Holdings Ltd
Per the firm's website.
Colleagues at F-Prime Capital Partners
Network14
βΆ2 more connections
Investors connected to Alexander in public investor directories β a warm-intro map.

.png)































